Trial Profile
Phase I trial investigating the tolerabilty of AE 37 in patients with prostate cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Apr 2019
Price :
$35
*
At a glance
- Drugs AE 37 (Primary) ; Granulocyte colony-stimulating factors
- Indications Prostate cancer
- Focus Adverse reactions; Pharmacodynamics
- 31 May 2013 Data was published in conjunction with the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO), according to a Generex Biotechnology Corporation media release.
- 14 Jun 2012 Results have been presented at ASCO-2012 according to a Generex Biotechnology Corporation media release. Results were also summarised in the media release.
- 18 May 2010 According to a Generex media release, results from this study are being published in the journal Clinical Cancer Research. The online publication date is 13 May 2010.